Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice

Journal of Cellular Biochemistry

Volumn 114, Issue 2, 2013, Pages 366-377

  Gauthaman, Kalamegam ^a   Fong, Chui Yee ^a   Arularasu, Suganya ^a   Subramanian, Arjunan ^a   Biswas, Arijit ^a   Choolani, Mahesh ^a   Bongso, Ariff ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer cell attenuation; Human Wharton's jelly stem cell conditioned medium and cell free lysate; Mammary adenocarcinoma; Osteosarcoma

Indexed keywords

ANNEXIN; AUTOPHAGY PROTEIN 5; BECLIN 1; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL DEATH; CELL FREE SYSTEM; CELL LYSATE; CELL MEMBRANE; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN WHARTON JELLY STEM CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WHARTON JELLY;

ANIMALS; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; NEOPLASMS; OSTEOSARCOMA; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 84872729730     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24367     Document Type: Article

References (50)

1. Angelucci S, Marchisio M, Di Giuseppe F, Pierdomenico L, Sulpizio M, Eleuterio E, Lanuti P, Sabatino G, Miscia S, Di Ilio C. 2010. Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci 8: 18-25.
2. Ayuzawa R, Doi C, Rachakatla RS, Pyle MM, Maurya DK, Troyer D, Tamura M. 2009. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett 280:31-37.
3. Bhardwaj A, Singh S, Singh AP. 2010. MicroRNA-based cancer therapeutics: Big hope from small RNAs. Mol Cell Pharmacol 2:213-219.
4. Bongso A, Fong CY, Gauthaman K. 2008. Taking stem cells to the clinic: Major challenges. J Cell Biochem 105:1352-1360.
5. Burstein HJ. 2011. Novel agents and future directions for refractory breast cancer. Semin Oncol 38:S17-S24.
6. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. 2010. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 18:223-231.
7. Chamberlain G, Fox J, Ashton B, Middleton J. 2007. Concise review: Mesenchymal stem cells - Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25:2739-2749.
8. Chao KC, Chao KF, Fu YS, Liu SH. 2008. Islet-like clusters derived from mesenchymal stem cells in Wharton's jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS ONE e1451:1-9.
9. Chao KC, Yang HT, Chen MW. 2011. Human umbilical cord mesenchymal stem cells suppress breast cancer tumorigenesis through direct cell-cell contact and internalization. J Cell Mol Med 16:1803-1815.
10. Colombo MP, Trinchieri G. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168.
11. Fan CG, Zhang Q, Zhou J. 2011. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev Rep 7:195-207.
12. Fong CY, Richards M, Manasi N, Biswas A, Bongso A. 2007. Comparative growth behaviour and characterization of stem cells from human Wharton's jelly. Reprod BioMed Online 15:708-718.
13. Fong CY, Subramanian A, Biswas A, Gauthaman K, Srikanth P, Hande M, Bongso A. 2010. Derivation efficiency, cell proliferation, frozen-thaw survival, stem cell properties and differentiation of human Wharton's jelly stem cells. Reprod BioMed Online 21:391-401.
14. Fong CY, Chak LL, Biswas A, Tan JH, Gauthaman K, Chan WK, Bongso A. 2011a. Human Wharton's jelly stem cells have unique transcriptome profiles compared to hESCs and other MSCs. Stem Cell Rev Rep 7:1-16.
15. Fong CY, Gauthaman K, Suganya C, Hao DL, Biswas A, Bongso A. 2011b. Human umbilical cord Wharton's Jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem 113:658-668.
16. Friedman R, Betancur M, Boissel L, Tuncer H, Cetrulo C, Klingemann H. 2007. Umbilical cord mesenchymal stem cells: Adjuvants for human cell transplantation. Biol Blood Bone Marrow Transplant 13:1477-1486.
17. Fritz V, Jorgensen C. 2008. Mesenchymal stem cells: An emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther 3:32-42.
18. Ganta C, Chiyo D, Ayuzawa R, Rachakatla R, Pyle M, Andrews G, Weiss M, Tamura M, Troyer D. 2009. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res 69:1815-1820.
19. Gauthaman K, Fong CY, Cheyyatraivendran S, Biswas A, Choolani M, Bongso A. 2012a. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem 113:2027-2039.
20. Gauthaman K, Fong CY, Cheyyatraivendran S, Subramanian A, Biswas A, Choolani M, Bongso A. 2012b. Human Wharton's jelly stem cells do not induce tumorigenesis unlike hESCs. Reprod BioMed Online 24:235-246.
21. Guise TA, O'Keefe R, Randall RL, Terek RM. 2009. Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am 91:724-732.
22. Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y, Ishiguro N. 2007. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 171:274-286.
23. Huang YC, Parolini O, La Rocca G, Deng L. 2012. Umbilical cord versus bone marrow derived mesenchymal stromal cells. Stem Cells Dev DOI: 10.1089/scd.2012.0216.
24. Karahuseyinglu S, Cinar O, Kilic E. 2007. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells 25:319-331.
25. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, StetlerStevenson W, Frank JA, Reitz M, Finkel T. 2006. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203:1235-1247.
26. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845.
27. La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacono M, Di Stefano A, Giannuzzi P, Marasà L, Cappello F, Zummo G, Farina F. 2009. Isolation and characterization of Oct4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: Differentiation potential and detection of new markers. Histochem Cell Biol 131:267-282.
28. Ma WW, Adjei AA. 2009. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111-137.
29. Ma Y, Hao X, Zhang S, Zhang J. 2012. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat 133:473-485.
30. Maurya DK, Doi C, Kawabata A, Pyle MM, King C, Wu Z, Troyer D, Tamura M. 2010. Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer 10:590-600.
31. Medicetty S, Bledsoe AR, Fahrenholtz CB, Troyer D, Weiss ML. 2004. Transplantation of pig stem cells into rat brain: Proliferation during the first 8 weeks. Exp Neurol 190:32-41.
32. Moser B, Wolf M, Walz A, Loetscher P. 2004. Chemokines: Multiple levels of leukocyte migration control. Trends Immunol 25:75-84.
33. Nikitovic D, Zafiropoulos A, Tzanakakis GN, Karamanos NK, Tsatsakis AM. 2005. Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25:2851-2856.
34. Prockop DJ. 2009. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths and changing paradigms. Mol Ther 17:939-946.
35. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X. 2008. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18:500-507.
36. Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. 2007. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 14:828-835.
37. Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC. 2011. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 18:488-495.
38. Siclari VA, Qin L. 2010. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5:1-10.
39. Subramanian A, Gan SU, Ngo KS, Gauthaman K, Biswas A, Choolani M, Bongso A, Fong CY. 2012. Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells J Cell Biochem 113:1886-1895.
40. Sun B, Yu KR, Bhandari DR, Jung JW, Kang SK, Kang KS. 2010. Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Lett 296:178-185.
41. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, Osterheld MC, Guillou L, Stamenkovic I. 2009. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69:1776-1781.
42. Taghizadeh RR, Cetrulo KJ, Cetrulo CL. 2011. Wharton's jelly stem cells: Future clinical applications. Placenta 32:S311-S315.
43. Tan ML, Choong PF, Dass CR. 2009. Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther 8:106-117.
44. Troyer DL, Weiss ML. 2008. Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26:591-599.
45. Wang XY, lan Y, He WY, Zhang L, Yao HY, Hou C. 2008. Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. Blood 111:2436-2443.
46. Weiss ML, Mitchell KE, Hix JE, Medicetty S, El-Zarkouny SZ, Grieger D, Troyer DL. 2003. Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp Neurol 182:288-299.
47. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. 2007. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705-1721.
48. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, Vanderwerff I. 2008. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 26:2865-2874.
49. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074-3081.
50. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. 2011. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4:16-25.